Common biomarker analysis of AD looks for changes of CSF Aβ42/40, phosphorylated tau (P-tau) and total tau (T-tau) [96] and neurogranin, a cerebral post-synaptic protein involved in long-term potentiation, whose elevation in the CSF appears specific to AD [97]. The gene discussed is MAPT; the disease is Alzheimer disease.